Vividion Therapeutics
Acquired
Leading the small molecule Revolution
- Headquarters
- San Diego, California
- Employees
- 201–500
- Founded
- 2016
- Business Model
- B2B
- Website
- vividion.com
- Total Funding
- $368.0M
- Last Round
- $135.0M Series CFeb 2021
About
Vividion Therapeutics is a San Diego-based biopharmaceutical company leveraging proprietary chemoproteomics technology to identify and drug previously undruggable protein targets for devastating cancers and immune disorders. Founded in 2016 as a spin-out of Scripps Research Institute, the company was acquired by Bayer AG in September 2021 for up to $2 billion and continues to operate as an autonomous subsidiary. Vividion has more than 200 employees and maintains active research and development programs.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account